INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Heart failure with preserved ejection fraction (HFpEF) affects approximately 50% of heart failure patients.
• Currently, no proven treatments exist to improve outcomes for HFpEF.
• The complex pathophysiology of HFpEF involves multiple abnormalities, including impaired nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) bioavailability.

Purpose of the Study:

• To assess the effect of inhaled inorganic nitrite on peak exercise capacity in patients with HFpEF.
• To explore inorganic nitrite as a therapeutic strategy to restore NO-cGMP signaling in HFpEF.
• To investigate the potential of inorganic nitrite to improve exercise tolerance in HFpEF.

Main Methods:

• The INDIE-HFpEF trial is a multicenter, randomized, double-blind, placebo-controlled, cross-over study.
• Participants with HFpEF will receive inhaled inorganic nitrite or a placebo.
• Peak exercise capacity will be the primary endpoint assessed.

Main Results:

• This section is not applicable as the abstract describes the study design and rationale, not the results.
• The study aims to determine if inorganic nitrite improves exercise capacity in HFpEF.
• Further research is needed to analyze the outcomes of the INDIE-HFpEF trial.

Conclusions:

• Inorganic nitrite represents a promising alternative strategy to enhance NO-cGMP signaling in HFpEF.
• The INDIE-HFpEF trial will provide crucial insights into the efficacy of inhaled inorganic nitrite for HFpEF.
• Restoring NO-cGMP bioavailability may offer a novel therapeutic approach for improving outcomes in HFpEF.